These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32788124)

  • 1. Patient outcomes in myeloproliferative neoplasm-related thrombosis: Insights from the National Inpatient Sample.
    Ulanja MB; Beutler BD; Antwi-Amoabeng D; Apanga PA; Moody AE; Willyard CE; Gullapalli N; Boampong-Konam K; Bowman AT
    Thromb Res; 2020 Oct; 194():72-81. PubMed ID: 32788124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Sankar K; Stein BL; Rampal RK
    Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm.
    Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Kim SY; Jo DY
    Korean J Intern Med; 2021 Sep; 36(5):1190-1203. PubMed ID: 34289585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sepsis-Related Outcomes of Patients with Philadelphia-Negative Myeloproliferative Neoplasms.
    Gonzalez-Mosquera LF; Moscoso B; Tobar P; Cardenas-Maldonado D; Podrumar AI; Mesa R; Cuenca JA
    Cancer Invest; 2023 May; 41(5):423-431. PubMed ID: 36883674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thrombosis in myeloproliferative neoplasms].
    Asakura H
    Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Pitfalls of Global Hemostasis Assays in Myeloproliferative Neoplasms and Future Challenges.
    Tiu A; Chiasakul T; Kessler CM
    Semin Thromb Hemost; 2024 Mar; 50(2):213-223. PubMed ID: 37068511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splanchnic Vein Thrombosis in Myelofibrosis-An Underappreciated Hallmark of Disease Phenotype.
    Beleva EA
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends and Inpatient Outcomes of Venous Thromboembolism-Related Admissions in Patients with Philadelphia-Negative Myeloproliferative Neoplasms.
    Katiyar V; Uprety A; Mendez-Hernandez A; Fuentes HE; Andrade XA; Zia M
    TH Open; 2019 Jul; 3(3):e203-e209. PubMed ID: 31321378
    [No Abstract]   [Full Text] [Related]  

  • 11. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
    Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Value of Kozak Gene Polymorphism for Thrombosis in Patients with Philadelphia-Negative MPNs.
    El-Ghonemy MS; El-Ashwah S; Denewer M; Soliman EA; El-Baiomy M; Elkerdawy H; El-Sebaie A
    Asian Pac J Cancer Prev; 2021 Apr; 22(4):1195-1201. PubMed ID: 33906312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.
    Rungjirajittranon T; Owattanapanich W; Ungprasert P; Siritanaratkul N; Ruchutrakool T
    BMC Cancer; 2019 Feb; 19(1):184. PubMed ID: 30819138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study.
    Hur JY; Choi N; Choi JH; Kim J; Won YW
    Thromb Res; 2024 Apr; 236():209-219. PubMed ID: 38461615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry.
    Varghese C; Immanuel T; Ruskova A; Theakston E; Kalev-Zylinska ML
    Curr Oncol; 2021 Apr; 28(2):1544-1557. PubMed ID: 33919650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms.
    Barzilai M; Kirgner I; Avivi I; Ellis M; Dally N; Rozovski U; Lavi N
    Eur J Haematol; 2019 Jun; 102(6):504-508. PubMed ID: 30941804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombosis among 1537 patients with JAK2
    Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
    Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
    Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
    Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms.
    Falanga A; Marchetti M; Schieppati F
    Hamostaseologie; 2021 Feb; 41(1):48-57. PubMed ID: 33588455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.